SAN DIEGO, Sept. 2 /PRNewswire/ --Results from studies related to Optimer Pharmaceutocation">Boston on September 12-15, 2010.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Fidaxomicin abstracts and speakers include:
“Randomized Controlled Trial (RCT) of Fidaxomicin (FDX) Versus Vancomycin (VAN) in Treatment of Recurrent Clostridium difficile Infection (CDI)”
Oral Presentation: Oliver Cornely, M.D.
icals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin,will be presentedat the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Tuesday, September 14, 20109:00 am - 9:15 am Eastern Time
Presentation number: L1-1305 in 253A
“Clostridium difficile Strain Type as Determined by Restriction Endonuclease Analysis (REA) Typing in Two Phase III Trials of Fidaxomicin vs Vancoymcin: Treatment Outcome for the Epidemic BI/NAP1/027 Strain”
Oral Presentation: Dale N. Gerding, M.D.
Tuesday, September 14, 20109:15 am - 9:30 am Eastern Time
Presentation number: L1-1306 in 253A
“Correlation of the ATLAS Bedside Scoring System And Its Components With Cure and Recurrence of Clostridium difficile Infection (CDI)”
Poster Presentation: Mark A. Miller, M.D.
Tuesday, September 14, 201011:15 am - 1:15 pm Eastern Time
Presentation number: K-1692 in Exhibit Hall B1
“Use of Concomitant Antibiotics (CA) Has a Deleterious Effect on Outcomes During Treatment for Clostridium difficile Infection (CDI)”
Poster Presentation: Kate Mullane, M.D.
Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time
Presentation number: K-1695 in Exhibit Hall B1
“Comparative Susceptibilities of Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence and Failure from Patients in a Phase III trial (004) of C difficile infection (CDI)”
Poster Presentation: Ellie J. Goldstein, M.D.
Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time
Presentation number: K-1691 in Exhibit Hall B1
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.
Contacts | |
Optimer Pharmaceuticals, Inc. | |
Christina Donaghy, Corporate Communications Manager | |
John D. Prunty, Chief Financial Officer & VP Finance | |
858-909-0736 | |
Canale Communications, Inc. | |
Jason I. Spark, Senior Vice President | |
619-849-6005 | |
SOURCE Optimer Pharmaceuticals, Inc.
